I agree that this site is using cookies. You can find further informations here.
X
Arlegui, Hugo
25  results:
Search for persons X
?
1

Clinical features, therapeutic choice and response by photo..:

Salle, Romain ; Tubach, Florence ; Arlegui, Hugo...
Clinical and Experimental Dermatology.  48 (2023)  11 - p. 1238-1246 , 2023
Link: https://doi.org/10.1093/..
 
?
2

Biologic tapering for patients with psoriasis with low dise..:

Aubert, Helene ; Arlegui, Hugo ; De Rycke, Yann...
British Journal of Dermatology.  188 (2022)  1 - p. 150-152 , 2022
Link: https://doi.org/10.1093/..
 
?
3

Evolution of Drug Survival with Biological Agents and Aprem..:

Bettuzzi, Thomas ; Bachelez, Hervé ; Beylot-Barry, Marie...
Acta Dermato-Venereologica.  102 (2022)  - p. adv00665 , 2022
Link: https://doi.org/10.2340/..
 
?
4

Using Discretely Integrated Condition Event Simulation To C..:

Arlegui, Hugo ; Nachbaur, Gaëlle ; Praet, Nicolas..
Clinical Therapeutics.  42 (2020)  10 - p. 1983-1991.e2 , 2020
Link: https://doi.org/10.1016/..
 
?
5

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towa..:

Arlegui, Hugo ; Bollaerts, Kaatje ; Bauchau, Vincent...
Drug Safety.  43 (2020)  11 - p. 1105-1120 , 2020
Link: https://doi.org/10.1007/..
 
?
6

Benefit–Risk Assessment of Vaccines. Part I: A Systematic R..:

Arlegui, Hugo ; Bollaerts, Kaatje ; Salvo, Francesco...
Drug Safety.  43 (2020)  11 - p. 1089-1104 , 2020
Link: https://doi.org/10.1007/..
 
?
7

Quantitative Benefit-Risk Models Used for Rotavirus Vaccina..:

Bégaud, Bernard ; Praet, Nicolas ; Nachbaur, Gaëlle.
Open Forum Infectious Diseases.  7 (2020)  4 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
8

Benefit Versus Risk Assessment of Rotavirus Vaccination in ..:

Ledent, Edouard ; Arlegui, Hugo ; Buyse, Hubert...
BioDrugs.  32 (2018)  2 - p. 139-152 , 2018
Link: https://doi.org/10.1007/..
 
?
9

Evolution of Drug Survival with Biological Agents and Aprem..:

BETTUZZI, Thomas ; BACHELEZ, Hervé ; BEYLOT-BARRY, Marie...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631244/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

Using Discretely Integrated Condition Event Simulation To C..:

ARLEGUI, Hugo ; NACHBAUR, G ; PRAET, N..
1879-114X (Electronic) 0149-2918 (Linking).  , 2020
Link: https://oskar-bordeaux.f..
 
?
11

Using Discretely Integrated Condition Event Simulation To C..:

Arlegui, Hugo ; NACHBAUR, G ; Praet, N..
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinthera.2020.08.013.  , 2020
Link: https://hal.archives-ouv..
 
?
12

Benefit–Risk Assessment of Vaccines. Part I: A Systematic R..:

Arlegui, Hugo ; Bollaerts, Kaatje ; Salvo, Francesco...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575467/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
13

Quantitative Benefit-Risk Models Used for Rotavirus Vaccina..:

Arlegui, Hugo ; NACHBAUR, G ; Praet, N.
info:eu-repo/semantics/altIdentifier/doi/10.1093/ofid/ofaa087.  , 2020
Link: https://hal.archives-ouv..
 
?
14

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towa..:

ARLEGUI, Hugo ; BOLLAERTS, K ; BAUCHAU, V...
1179-1942 (Electronic) 0114-5916 (Linking).  , 2020
Link: https://oskar-bordeaux.f..
 
?
15

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towa..:

Arlegui, Hugo ; BOLLAERTS, K ; Bauchau, V...
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40264-020-00982-9.  , 2020
Link: https://hal.archives-ouv..
 
1-15